Effects of ASI (arginine-silicate-inositol) complex (0 mg/kg; 500 mg/kg; 1000 mg/kg) supplementation on the expression levels of the calcium transporters and tight junction proteins: calbindin-D28k (panel A), occludin (panel B), N sodium-calcium exchanger (NCX1, panel C), zonula occludens-1 (ZO-1, panel D), plasma membrane calcium ATPase (PMCA1, panel E), and vitamin D receptor (VDR, panel F) in duodenum. Tissue calbindin-D28k, occludin, NCX1, ZO-1, PMCA1, and VDR expressing levels (Panel G) western blot strips.

<p>Data are expressed as percent of control value. Each bar represents the mean and standard error of mean. Blots were repeated at least 3 times (n = 3). P<0.05; **P<0.01; ***P<0.001.</p

Effects of ASI (arginine-silicate-inositol) complex (♦, 0 mg/kg; ■, 500 mg/kg; ▲, 1000 mg/kg) supplementation on egg production.

<p>Covariate is average initial egg production of all chickens first 7 days prior to the experimental period at age of 25 weeks. Pooled SEM = 0.27.</p

Effects of dietary ASI (arginine-silicate-inositol) complex supplementation on serum parameters and calcium metabolism^a.

<p>Effects of dietary ASI (arginine-silicate-inositol) complex supplementation on serum parameters and calcium metabolism<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189329#t003fn001" target="_blank">^a</a>.</p

Image2_Cannabinoid compounds in combination with curcumin and piperine display an anti-tumorigenic effect against colon cancer cells.JPEG

Currently, use of cannabinoids is limited to improve adverse effects of chemotherapy and their palliative administration during treatment is curiously concomitant with improved prognosis and regressed progression in patients with different tumor types. Although, non-psychoactive cannabidiol (CBD) and cannabigerol (CBG) display antineoplastic effects by repressing tumor growth and angiogenesis both in cell line and animal models, their use as chemotherapeutic agents is awaiting further investigation. Both clinical and epidemiological evidence supported by experimental findings suggest that micronutrients such as curcumin and piperine may present a safer strategy in preventing tumorigenesis and its recurrence. Recent studies demonstrated that piperine potentiates curcumin’s inhibitory effect on tumor progression via enhancing its delivery and therapeutic activity. In this study, we investigated a plausible therapeutic synergism of a triple combination of CBD/CBG, curcumin, and piperine in the colon adenocarcinoma using HCT116 and HT29 cell lines. Potential synergistic effects of various combinations including these compounds were tested by measuring cancer cell proliferation and apoptosis. Our findings revealed that different genetic backgrounds of HCT116 and HT29 cell lines resulted in divergent responses to the combination treatments. Triple treatment showed synergism in terms of exhibiting anti-tumorigenic effects by activating the Hippo YAP signaling pathway in the HCT116 cell line.</p

Image1_Cannabinoid compounds in combination with curcumin and piperine display an anti-tumorigenic effect against colon cancer cells.JPEG

Currently, use of cannabinoids is limited to improve adverse effects of chemotherapy and their palliative administration during treatment is curiously concomitant with improved prognosis and regressed progression in patients with different tumor types. Although, non-psychoactive cannabidiol (CBD) and cannabigerol (CBG) display antineoplastic effects by repressing tumor growth and angiogenesis both in cell line and animal models, their use as chemotherapeutic agents is awaiting further investigation. Both clinical and epidemiological evidence supported by experimental findings suggest that micronutrients such as curcumin and piperine may present a safer strategy in preventing tumorigenesis and its recurrence. Recent studies demonstrated that piperine potentiates curcumin’s inhibitory effect on tumor progression via enhancing its delivery and therapeutic activity. In this study, we investigated a plausible therapeutic synergism of a triple combination of CBD/CBG, curcumin, and piperine in the colon adenocarcinoma using HCT116 and HT29 cell lines. Potential synergistic effects of various combinations including these compounds were tested by measuring cancer cell proliferation and apoptosis. Our findings revealed that different genetic backgrounds of HCT116 and HT29 cell lines resulted in divergent responses to the combination treatments. Triple treatment showed synergism in terms of exhibiting anti-tumorigenic effects by activating the Hippo YAP signaling pathway in the HCT116 cell line.</p

Pearson’s correlation coefficients (r) among egg shell quality, vitamin D, calcium metabolism, and calcium transport proteins’ expressions.

<p>Pearson’s correlation coefficients (r) among egg shell quality, vitamin D, calcium metabolism, and calcium transport proteins’ expressions.</p

Effects of dietary ASI (arginine-silicate-inositol) complex supplementation on performance and egg quality^a.

<p>Effects of dietary ASI (arginine-silicate-inositol) complex supplementation on performance and egg quality<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189329#t002fn001" target="_blank">^a</a>.</p

Table1_Cannabinoid compounds in combination with curcumin and piperine display an anti-tumorigenic effect against colon cancer cells.docx

Currently, use of cannabinoids is limited to improve adverse effects of chemotherapy and their palliative administration during treatment is curiously concomitant with improved prognosis and regressed progression in patients with different tumor types. Although, non-psychoactive cannabidiol (CBD) and cannabigerol (CBG) display antineoplastic effects by repressing tumor growth and angiogenesis both in cell line and animal models, their use as chemotherapeutic agents is awaiting further investigation. Both clinical and epidemiological evidence supported by experimental findings suggest that micronutrients such as curcumin and piperine may present a safer strategy in preventing tumorigenesis and its recurrence. Recent studies demonstrated that piperine potentiates curcumin’s inhibitory effect on tumor progression via enhancing its delivery and therapeutic activity. In this study, we investigated a plausible therapeutic synergism of a triple combination of CBD/CBG, curcumin, and piperine in the colon adenocarcinoma using HCT116 and HT29 cell lines. Potential synergistic effects of various combinations including these compounds were tested by measuring cancer cell proliferation and apoptosis. Our findings revealed that different genetic backgrounds of HCT116 and HT29 cell lines resulted in divergent responses to the combination treatments. Triple treatment showed synergism in terms of exhibiting anti-tumorigenic effects by activating the Hippo YAP signaling pathway in the HCT116 cell line.</p

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S11

Aim: Our main objectives were to compare the effects of Rejuveinix (RJX), dexamethasone (DEX) and their combination on the severity of sepsis and survival outcome in an animal model of fatal sepsis. Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. Data were analyzed using standard methods. Results & conclusion: RJX exhibited potent anti-inflammatory activity in the murine sepsis model. The combination of RJX plus DEX was more effective than either agent alone, decreased the inflammatory cytokine responses and associated organ damage, and improved the survival outcome in mice. In the phase I clinical study, RJX plus DEX was well tolerated by COVID-19 patients.</p

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S4

Aim: Our main objectives were to compare the effects of Rejuveinix (RJX), dexamethasone (DEX) and their combination on the severity of sepsis and survival outcome in an animal model of fatal sepsis. Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. Data were analyzed using standard methods. Results & conclusion: RJX exhibited potent anti-inflammatory activity in the murine sepsis model. The combination of RJX plus DEX was more effective than either agent alone, decreased the inflammatory cytokine responses and associated organ damage, and improved the survival outcome in mice. In the phase I clinical study, RJX plus DEX was well tolerated by COVID-19 patients.</p